A 26 Week, Randomized, Double Blind, Multinational, Multicenter, Active Controlled, 2-arm Parallel Group Trial Comparing CHF 5993 100/6/12.5 μg pMDI (Fixed Combination of Extrafine Formulation of Beclometasone Dipropionate Plus Formoterol Fumarate Plus Glycopyrronium Bromide) to CHF 1535 22/6 μg pMDI (Fixed Combination of Extrafine Formulation of Beclometasone Dipropionate Plus Formoterol Fumarate) in Subjects With Asthma Uncontrolled on Medium Doses of Inhaled Corticosteroids in Combination With Long-Acting β2-Agonists
Latest Information Update: 02 Oct 2024
At a glance
- Drugs Beclometasone/formoterol/glycopyrrolate (Primary) ; Beclometasone/formoterol; Corticosteroids; Formoterol; Salmeterol; Vilanterol
- Indications Asthma
- Focus Therapeutic Use
- Acronyms MiSTIC
- Sponsors Chiesi Farmaceutici SpA
- 30 May 2024 This trial has been completed in Poland, according to European Clinical Trials Database record.
- 29 May 2024 This trial has been completed in Greece and Latvia, according to European Clinical Trials Database record.
- 11 May 2024 This study has been completed in Czech Republic and Bulgaria, according to European Clinical Trials Database record.